CytomX Therapeutics Inc (CTMX) — Cash Flow-to-Debt Ratio
CytomX Therapeutics Inc (CTMX) has a Cash Flow-to-Debt Ratio of -0.65x as of March 2026, meaning its operating cash flow of $-25.55 Million could theoretically repay -1% of its total liabilities ($39.41 Million) in one year. See CTMX free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
CytomX Therapeutics Inc Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for CytomX Therapeutics Inc across 13 annual periods. Also explore CTMX net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for CytomX Therapeutics Inc (2013–2025)
Year-by-year debt coverage analysis for CytomX Therapeutics Inc. For market capitalisation and broader financial context, see CTMX market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.44x | $-75.59 Million | $52.56 Million | ▼ -101.8% |
| 2024 | -0.71x | $-86.23 Million | $120.99 Million | ▼ -217.0% |
| 2023 | -0.22x | $-56.03 Million | $249.24 Million | ▲ +29.7% |
| 2022 | -0.32x | $-110.79 Million | $346.64 Million | ▲ +32.9% |
| 2021 | -0.48x | $-119.03 Million | $250.03 Million | ▼ -3417.1% |
| 2020 | 0.01x | $5.26 Million | $366.44 Million | ▲ +103.0% |
| 2019 | -0.48x | $-140.48 Million | $290.17 Million | ▼ -109.1% |
| 2018 | -0.23x | $-75.52 Million | $326.23 Million | ▼ -144.5% |
| 2017 | 0.52x | $170.37 Million | $327.75 Million | ▲ +3186.5% |
| 2016 | -0.02x | $-2.03 Million | $120.65 Million | ▲ +95.6% |
| 2015 | -0.39x | $-27.41 Million | $71.15 Million | ▼ -283.7% |
| 2014 | 0.21x | $31.80 Million | $151.60 Million | ▲ +253.1% |
| 2013 | -0.14x | $-8.01 Million | $58.46 Million | — |